Tag Archives: Ritu Baral
ACADIA Pharmaceuticals Inc (ACAD) Gets a Buy Rating from Cowen & Co.
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on ACADIA Pharmaceuticals Inc (ACAD – Research Report), with a price target of $66. The company’s shares closed last Monday at $39.48, close to its
Orchard Therapeutics PLC (ORTX) Gets a Buy Rating from Cowen & Co.
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Orchard Therapeutics PLC (ORTX – Research Report), with a price target of $27. The company’s shares closed last Monday at $14.70. According to TipRanks.com,
Cowen & Co. Maintains a Buy Rating on Scholar Rock Holding Corp (SRRK)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Scholar Rock Holding Corp (SRRK – Research Report) yesterday. The company’s shares closed last Monday at $10.71, close to its 52-week low of $9.30. According to TipRanks.com, Baral is
Analysts Offer Insights on Healthcare Companies: Krystal Biotech Inc (NASDAQ: KRYS), Prevail Therapeutics Inc (NASDAQ: PRVL) and Intec Pharma Ltd (NASDAQ: NTEC)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Krystal Biotech Inc (KRYS – Research Report), Prevail Therapeutics Inc (PRVL – Research Report) and Intec Pharma Ltd (NTEC – Research Report). Krystal
Cowen & Co. Sticks to Their Buy Rating for Morphic Holding Inc (MORF)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Morphic Holding Inc (MORF – Research Report). The company’s shares opened today at $27.38. According to TipRanks.com, Baral is a 5-star analyst with an
Avrobio Inc (AVRO) Gets a Buy Rating from Cowen & Co.
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio Inc (AVRO – Research Report) yesterday. The company’s shares closed on Friday at $19.24. According to TipRanks.com, Baral is a 5-star analyst with an average return of 22.4%
